DEF: Minerva Neurosciences Seeks Shareholder Approval for Capital Expansion

Minerva Neurosciences will hold its 2025 Annual Meeting to vote on increasing authorized shares, approving Series A Preferred Stock conversion, and amending its equity incentive plan, crucial for future funding and talent retention.

Summary

• Minerva Neurosciences, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on December 22, 2025, at 9:30 a.m. Eastern time.
• Stockholders will vote on the election of two Class II directors, Fouzia Laghrissi-Thode and Inderjit Kaul, to serve until the 2028 Annual Meeting.
• A key proposal is to amend the Certificate of Incorporation to increase authorized common stock from 125,000,000 to 250,000,000 shares.
• Stockholder approval is sought for the issuance of common stock upon conversion of Series A Convertible Voting Preferred Stock, including shares from warrants, to comply with Nasdaq Listing Rules.
• An amendment to the 2013 Equity Incentive Plan is proposed to increase authorized shares for issuance by 12,500,000 shares.
• An advisory vote on executive compensation and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025 are also on the agenda.
• The company closed a private placement on October 23, 2025, raising $80 million in gross proceeds from Series A Preferred Stock.
• As of September 30, 2025, the company had an accumulated deficit of $405.1 million and a net loss of $9.8 million for the nine months ended September 30, 2025.
• The conversion of Series A Preferred Stock, if approved, will result in each share converting into 473 shares of common stock at a conversion price of $2.11 per share.

Sentiment

Score: 3

Explanation: The filing highlights significant ongoing losses and the need for substantial future capital, indicating a challenging financial position. While a recent capital raise provides some relief, the company remains pre-revenue with a high accumulated deficit and a majority of employee options underwater, suggesting poor past performance and continued financial pressure. The proposals are primarily aimed at enabling future financing and retaining talent, rather than reporting positive operational results.

Positives

• Successfully closed a private placement on October 23, 2025, raising $80 million in gross proceeds, providing capital for future operations.
• The proposed increase in authorized shares and amendment to the equity incentive plan aim to provide flexibility for future capital raises, strategic partnerships, and attracting/retaining key talent.
• The company is actively advancing its product candidates, including roluperidone for schizophrenia, with a Phase 3 confirmatory trial underway.
• The Board has a lead independent director (Dr. Kupfer) to reinforce independence and oversight.

Negatives

• The company has incurred significant operating losses since inception, with an accumulated deficit of $405.1 million as of September 30, 2025.
• Reported a net loss of $9.8 million for the nine months ended September 30, 2025.
• A substantial portion (53.5%) of outstanding employee and consultant stock options are currently underwater, potentially impacting motivation and retention.
• The company has not yet received regulatory approvals for any product candidates and has not generated revenue from sales or licenses.
• The Series A Preferred Stock has protective provisions and senior rights (e.g., 2X liquidation preference) until stockholder approval for conversion is obtained, which could be dilutive and impact common stockholders.

Risks

• Failure to obtain stockholder approval for the increase in authorized shares (Proposal 2) could hinder future capital raising efforts, delay development, and preclude strategic opportunities.
• Failure to obtain stockholder approval for the conversion of Series A Preferred Stock (Proposal 3) would keep the preferred stock senior in dividend and liquidation rights, and subject to protective provisions, potentially impacting common stockholders.
• Lack of sufficient unissued and unreserved authorized shares of common stock (if Proposal 2 and 4 are not approved) could adversely impact the ability to attract, retain, and motivate highly qualified personnel through equity incentives.
• The issuance of additional common stock, if approved, will result in dilution of earnings per share and voting rights for current common stockholders.
• The company's success depends on its ability to attract, retain, and motivate highly qualified management and clinical personnel in a competitive biopharmaceutical industry.
• The company has not received any regulatory approvals to commercialize product candidates and has not generated revenue from sales or licenses, indicating ongoing reliance on capital raises.
• The company expects to continue incurring net losses and negative cash flows from operating activities for the foreseeable future.
• The Warrants (Preferred Tranche A and B) are subject to forfeiture if the applicable Investor engages in Short Sales, and Tranche B Warrants are subject to reduction if the investor sells Series A Preferred Stock or converted common stock before exercisability.

Future Outlook

The company anticipates requiring additional capital in the long-term to advance the development, regulatory approval process, and potential commercialization of roluperidone and other future product candidates. It regularly considers fundraising opportunities and aims to act quickly if market conditions are favorable. The proposed increase in authorized shares is intended to provide the necessary flexibility for these future capital needs and to support employee equity incentives.

Management Comments

• We believe hosting a virtual meeting enables increased stockholder participation and improves meeting efficiency and our ability to communicate effectively with our stockholders, while lowering the cost of conducting the Annual Meeting.
• Our Board believes it is appropriate to increase our authorized shares of Common Stock and Preferred Stock to provide us with additional flexibility to promptly and appropriately use our Common Stock for business and financial purposes in the future, as well as to have sufficient shares available to provide appropriate equity incentives for our employees and other eligible service providers.
• If this Proposal 2 is not approved, we may not be able to raise future capital without first obtaining stockholder approval for an increase in the number of authorized shares of Common Stock.
• We believe that equity awards are a key element underlying our ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully and implement our plans to advance the clinical programs of roluperidone.
• Our Compensation Committee and our Board feel these equity incentive holdings are inadequate to retain and motivate these key individuals critical to our continued success.

Industry Context

Minerva Neurosciences operates in the highly competitive biopharmaceutical industry, focusing on product candidates like roluperidone for schizophrenia. The company's need for significant capital raises and reliance on equity incentives for talent retention are common characteristics of early-stage biopharmaceutical companies that have not yet commercialized products or generated revenue. The ongoing Phase 3 confirmatory trial for roluperidone highlights the typical long and costly development cycles in this sector, where regulatory approvals are critical milestones for valuation and future success. The participation of institutional investors like Federated Hermes and strategic partners like Boehringer Ingelheim in private placements reflects the industry's reliance on specialized funding for R&D-intensive ventures.

Comparison to Industry Standards

• The company's accumulated deficit of $405.1 million and ongoing net losses are typical for a biopharmaceutical company in the clinical development stage, as significant R&D expenses are incurred before potential revenue generation.
• The reliance on equity incentives and the need to increase authorized shares for future grants are standard practices in the biotech industry to attract and retain highly skilled scientific and executive talent, often competing with larger pharmaceutical companies or other well-funded startups.
• The use of private placements with institutional and strategic investors (like Federated Hermes and Boehringer Ingelheim) for capital raises is a common financing mechanism for biotech companies, especially those with promising but unapproved drug candidates.
• The protective provisions granted to Series A Preferred Stock holders prior to common stock conversion are typical in such financing rounds, offering downside protection to early investors.
• The "say-on-pay" advisory vote on executive compensation and the ratification of the independent auditor are standard corporate governance practices for publicly traded U.S. companies, aligning with SEC and Nasdaq requirements.

Management Changes

Corporate Governance

Related Party Transactions

• Consulting Agreement with Dr. Inderjit Kaul: Entered into on November 14, 2025, for clinical trial workstreams and related services at $450 per hour for 25-30 hours per month for a six-month initial term. Includes a Consultant Option to purchase 0.7% of the Share Total, with vesting tied to roluperidone Phase 3 trial milestones.
• 2025 Private Placement: On October 21, 2025, the company entered into a securities purchase agreement with certain accredited investors, including Federated Hermes Kaufmann Funds (a beneficial owner of more than 5% of capital stock), to issue and sell 80,000 shares of Series A Preferred Stock and warrants for $80 million gross proceeds. Federated Hermes Kaufmann Funds purchased $8,500,000 worth of these securities.
• Support Agreements: Concurrently with the 2025 Private Placement, Federated Hermes Kaufmann Funds and Boehringer Ingelheim International GmbH (a beneficial owner of more than 5% of capital stock) entered into support agreements to vote their common stock in favor of Proposals 3 (Series A Preferred Stock conversion), 4 (2013 Equity Incentive Plan amendment), and other customary annual meeting matters.
• 2023 Private Placement: On June 27, 2023, the company entered into a securities purchase agreement with Federated Hermes Kaufmann Funds and Boehringer Ingelheim International GmbH (collectively, the 2023 Investors) to sell 1,425,000 common shares at $10.00 per share and 575,575 pre-funded warrants at $9.99 per warrant, generating $19.6 million net proceeds. Boehringer Ingelheim International GmbH gained a right to designate a board observer.
• Indemnification Agreements: The company has entered into indemnification agreements with each of its directors and certain executive officers, requiring indemnification to the fullest extent permitted by Delaware law and advancement of expenses.

Stakeholder Impact

• Shareholders: Potential significant dilution from the proposed increase in authorized common stock (Proposal 2) and the conversion of Series A Preferred Stock (Proposal 3), as well as future equity awards (Proposal 4). Voting rights and earnings per share will be diluted. However, approval of these proposals is deemed necessary for future capital raises and strategic growth, which could ultimately benefit long-term shareholders.
• Employees: The amendment to the 2013 Equity Incentive Plan (Proposal 4) is crucial for attracting, retaining, and motivating key personnel through equity awards, especially given that 53.5% of current options are underwater. This aims to align employee interests with company performance.
• Customers: No direct impact mentioned, as the company is pre-revenue and focused on R&D. Indirectly, successful capital raises and talent retention could accelerate product development, potentially benefiting future patients.
• Suppliers: No direct impact mentioned.
• Creditors: The capital raises provide additional funding, which could improve the company's liquidity and ability to meet its obligations, potentially benefiting creditors. The protective provisions for Series A Preferred Stock holders prior to conversion offer them a senior position.
• Management: Executive compensation is subject to an advisory vote (Proposal 5). Employment agreements include change-in-control and severance benefits. The proposed increase in equity incentive shares is intended to support management and key personnel retention.
• Directors: Two Class II directors are up for election. Director compensation includes cash retainers and equity awards, with changes to the Director Compensation Plan effective January 1, 2025.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on December 22, 2025, to vote on the proposed matters.
• If Proposal 3 is approved, file a registration statement on Form S-3 for the resale of common stock issuable upon conversion of Series A Preferred Stock within 15 days of approval announcement.
• Use commercially reasonable efforts to have the S-3 registration statement declared effective within 21 days (or 45 days if SEC reviews).
• Keep the S-3 registration statement effective until all registrable shares are resold or no registrable shares remain.
• Continue advancing the development, regulatory approval process, and potential commercialization of roluperidone and other product candidates.
• If Proposal 3 is not approved, resubmit the Conversion Stockholder Approval for approval at least annually until obtained.
• Dr. Kaul's Consultant Option vesting is tied to the public announcement of the primary endpoint of the Phase 3 confirmatory trial of roluperidone in schizophrenia and safety data from the 40-week relapse assessment phase.

Key Dates

Recommendation

The filing outlines critical proposals necessary for Minerva Neurosciences to continue its operations, particularly regarding future capital raises and employee retention. While the recent $80 million private placement provides some near-term liquidity, the company remains pre-revenue with substantial accumulated losses and a majority of employee stock options underwater, indicating significant past underperformance and ongoing financial challenges. The proposed increase in authorized shares and equity plan amendments are essential for the company's long-term viability and ability to fund its clinical programs, but they also imply substantial future dilution for existing common stockholders. Given the high-risk nature of a pre-commercial biopharmaceutical company, coupled with the necessity of these dilutive actions for survival, a 'hold' recommendation is appropriate. Investors should monitor the outcome of the shareholder votes and the progress of roluperidone's clinical trials, as these will be key determinants of future value. The current situation presents both the risk of further dilution and the potential for significant upside if clinical milestones are met and regulatory approvals are secured.

Keywords

Minerva Neurosciences, SEC Filing, Proxy Statement, Shareholder Meeting, Authorized Shares, Common Stock, Series A Preferred Stock, Equity Incentive Plan, Executive Compensation, Director Election, Corporate Governance, Capital Raise, Dilution, Nasdaq Listing Rules, Roluperidone, Schizophrenia, Biopharmaceutical, Clinical Trials, Risk Management, Financial Reporting